Figure legends:
Figure 1. Kinetics of anti-S1/S2 IgG titres after the second
BNT162b2 vaccine dose, 6 months later, and after the third dose in AIIRD
patients and controls.
AIIRD, autoimmune inflammatory rheumatic diseases
Figure 2. Kinetics of anti-S1/S2 IgG titres after the second
BNT162b2 vaccine dose, 6 months later, and after the third dose in AIIRD
patients grouped by diagnosis and in controls.
AIIRD, autoimmune inflammatory rheumatic diseases; JIA, Juvenile
Idiopathic Arthritis; SLE, Systemic Lupus Erythematosus.
Figure 3. Time from last BNT162b2 vaccine dose to COVID-19
breakthrough infection in healthy adolescents and those with AIIRD.